+ Incentive stock options
3+ days a week in office (Billerica, MA)
On-demand gene to protein synthesis
Be an early applicant
+ Incentive stock options
3+ days a week in office (Billerica, MA)
101-200 employees
To solve biological inaccessibility.
Founded out of research at the University of Cambridge, Nuclera is a biotech company developing protein-printing technologies to make proteins more accessible to everyone. In doing so, the bioprinter company enables life science researchers to accelerate breakthrough improvements in human health due to better access to biomolecules.
The company is somewhat revolutionary, seeing as developing proteins has long been a time-consuming and complicated process. Rather than taking weeks, months, or years, Nuclera’s eProtein desktop bioprinting technology does so in hours.
Trust in the product is marked by substantial funding between 2018 and 2022. Its extended Series C round, completed in 2026, is being used to ramp up the development of its eProtein Discovery system, maximising the impact of the proteins it prints.

Freddie
Company Specialist at Welcome to the Jungle
Jan 2026
$12m
SERIES C
Oct 2025
$69.1m
GROWTH EQUITY VC
Histon, UK
Gordon McInroy
(Co-Founder & COO)Previously acted as a Postdoctoral Research Associate for the University of Cambridge, before founding and acting as CSO for Nuclera.
Michael Chen
(Co-Founder & CEO)Previously studied at the University of Cambridge, National Institutes of Health, and Georgia Institute of Technology.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 1 more job at Nuclera
